Zymeworks Inc Common Stock

Zymeworks Inc Common Stock

Yahoo Finance • 22 hours ago

Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal

Zymeworks (ZYME) has drawn fresh attention after two October announcements: new Phase 1 data for its antibody drug conjugate ZW191 in ovarian cancer, and a wide-ranging licensing deal with Roche for trispecific candidate ZW209. Those cata... Full story

Yahoo Finance • 13 days ago

Zymeworks stock surges on $813M Roche licensing deal

Investing.com -- Zymeworks Inc (NASDAQ:ZYME) shares rose 5.5% in premarket trading Friday following the announcement of a global license and collaboration agreement with Roche for ZW209, a T cell engager targeting DLL3, in a deal worth up... Full story

Yahoo Finance • 13 days ago

Zymeworks Signs Roche Deal with $55 Million Upfront, Up to $718 Million in Milestones

Zymeworks (ZYME) said Friday it signed an exclusive global license and collaboration agreement with PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 13 days ago

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

Zymeworks Inc. Zymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 million in additional development, commercial and sales-based milestones Zyme... Full story

Yahoo Finance • last month

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

Zymeworks Inc. Acquisition diversifies durable cash flows and advances Zymeworks' strategy to build a productive R&D company with a growing portfolio of revenue-generating assets YUPELRI® expected to contribute immediately accretive reven... Full story

Yahoo Finance • 2 months ago

JAZZ Rises on Updated OS Results From Gastric Cancer Study

Jazz Pharmaceuticals JAZZ announced second interim top-line overall survival (OS) results from the phase III HERIZON-GEA-01 study, which evaluated different combination regimens involving its marketed drug, Ziihera (zanidatamab) as a first... Full story

Yahoo Finance • 2 months ago

Zymeworks Shares Rise Ahead of Key FDA Decision on Zanidatamab

Medical research ©rawpixel Zymeworks (NASDAQ:ZYME) shares climbed nearly 4.0% in pre-market trading as investors positioned themselves ahead of an important U.S. regulatory decision on zanidatamab, expected the following day. The FDA's P... Full story

Yahoo Finance • 3 months ago

Zymeworks gains following addition to Citi catalyst watch

[Wall Street sign in Lower Manhattan, NYC] georgeclerk * Zymeworks (ZYME [https://seekingalpha.com/symbol/ZYME]) is up ~2% in Monday trading after Citi added the stock to its 90-day catalyst watch list. * The bank sees shares rising d... Full story

Yahoo Finance • 4 months ago

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biothe... Full story

Yahoo Finance • 4 months ago

Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead?

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Zymeworks Inc. (NASDAQ:ZYME) is one of the best biotech stocks on this list. TheFly reported on June 9 that Truist Securities initiated coverage of ZY... Full story

Yahoo Finance • 4 months ago

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index up 0.1% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 5 months ago

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression levelConfirmed objective response rate (cORR) of 78.6% in FRα-positive (≥75% at PS2+) platinum-resistant ovarian c... Full story

Yahoo Finance • 6 months ago

Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million

What happened According to a recent SEC filing, Capricorn Fund Managers Ltd initiated a new stake in Axogen(NASDAQ:AXGN) during the first quarter of 2026. The fund acquired 687,600 shares, with an estimated transaction value of $22.36 mil... Full story

Yahoo Finance • 6 months ago

Capricorn Fund Managers Dumps $18.4 Million Worth of Waystar Stock in Q1

What happened According to an SEC filing dated April 24, 2026, Capricorn Fund Managers reduced its stake in Waystar(NASDAQ:WAY) by 692,554 shares during the first quarter of 2026. The estimated transaction value was $18.38 million, calcul... Full story

Yahoo Finance • 6 months ago

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

ZW191 demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expressionConfirmed objective response rate (cORR) of 61% at doses 6.4-9.6 mg/kg in platinum resistant ovarian canc... Full story

Yahoo Finance • 7 months ago

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Six poster presentations showcase Zymeworks’ next-generation ADC programs, including multiple first-in-class pan-RAS inhibitor ADCs Data highlight efficacy, tumor-selective delivery, and favorable tolerability across multiple solid tumor m... Full story

Yahoo Finance • 7 months ago

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, reg... Full story

Yahoo Finance • 8 months ago

Zymeworks Q4 Earnings Call Highlights

Zymeworks logo Zymeworks Offers Hope for More than Just Long-Term Investors Zymeworks (NASDAQ:ZYME) executives used the company’s fourth-quarter 2025 results call to highlight updated clinical data for its partnered HER2 antibody zanidat... Full story

Yahoo Finance • 8 months ago

Zymeworks Reports FY25 Results, Secures $250 Million Royalty Financing

(RTTNews) - Zymeworks Inc. (ZYME) has reported its fourth-quarter and full-year 2025 financial results while announcing a major $250 million royalty-backed financing agreement with Royalty Pharma, strengthening its balance sheet and extend... Full story

Yahoo Finance • 8 months ago

Zymeworks Secures $250 Mln Royalty Funding Deal With Royalty Pharma

(RTTNews) - Zymeworks Inc. (ZYME), a clinical-stage biopharmaceutical company, on Monday entered into a $250 million royalty funding agreement with Royalty Pharma plc (RPRX), a buyer of biopharmaceutical royalties, through a non-recourse r... Full story